Preventing the danger of unwanted CAR expression during lentivirus production
Join this exclusive webinar to discover advanced strategies for enhancing the quality of lentiviral (LV) vectors in cell therapy manufacturing.
Quality defects in LV vectors can significantly affect the efficacy and safety of final cell therapies. Despite their critical importance, there has been minimal focus on controlling and monitoring the quality of LV vectors used in cell therapy manufacture. Of particular concern is the risk of ‘breakthrough expression’ of the transgene, leading to CAR expression in producer cells and on the surface of the LV particle.
In this webinar, Lentitek will demonstrate how its promoter system is designed to significantly reduce breakthrough expression of the transgene in producer cells, maximizing the functional LV titer during anti-CD19 CAR vector production. Additionally, the webinar will showcase the Leprechaun platform from Unchained Labs, which promises precise identification and monitoring of CAR expression on the LV surface. This webinar is essential for professionals dedicated to improving quality and safety of cell therapies.
Presenter: Dr. Alex Shephard (Market Manager, Cell Therapy, Unchained Labs)
Presenter: Dr. Adam Inche (Founder & CEO, Lentitek)
